Laurie Smaldone Alsup

Dr. Smaldone Alsup, 65, has served as a director of the Company since June 2015 and is a member of the Audit and Risk Management Committee of the Board of Directors. She has a BA from Fordham College and an MD from Yale University, where she completed her residency in Internal Medicine and fellowship in Medical Oncology. Dr. Smaldone Alsup is Chief Operating Officer and Chief Scientific Officer of NDA Group AB, a leading drug development consulting company, which merged in 2016 with PharmApprove, where Dr. Smaldone Alsup was President and Chief Scientific Officer. She was previously Chief Executive Officer of Phytomedics, prior to which she held clinical and regulatory leadership roles at Bristol Myers Squibb, including Senior Vice President of Global Regulatory Science and Vice President of Corporate Strategy and Business Risk Management. Dr. Smaldone Alsup is also a former director of KaloBios Pharmaceuticals and has served with numerous professional and charitable organizations including the Cancer Institute of New Jersey, the Conference Board Strategic Risk Management Council and the McCarter Theatre in Princeton, New Jersey.